Triumeq PD - (60mg/5mg/30mg; Tablet for Suspension)

Generic Name	Abacavir Sulfate, Dolutegravir and Lamivudine	Innovator	VIIV Healthcare
Dosage	60mg/5mg/30mg; Tablet for Suspension	Branded US Sales	More Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	TRIUMEQ PD is a combination of dolutegravir (integrase strand transfer inhibitor [INSTI]), abacavir, and lamivudine (both nucleoside analogue reverse transcriptase inhibitors) indicated for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 10 kg
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** \ *********	-**-	*** *********	********* ********	******* *** **** (***** ******) *** *** ****

Chronology Of Events